Mass Balance Study of MT-3995
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT02900235
- Locations
- 🇬🇧
Investigational center, City name, United Kingdom
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 144
- Registration Number
- NCT02834442
- Locations
- 🇬🇧
Investigational center, United Kingdom, United Kingdom
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
Phase 1
Completed
- Conditions
- Vasomotor Symptoms
- Interventions
- Drug: MT-8554 low doseDrug: MT-8554 middle doseDrug: MT-8554 high doseDrug: Placebo
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT02803268
- Locations
- 🇩🇪
Investigational center, City name, Germany
An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy
Phase 2
Completed
- Conditions
- Diabetic Nephropathy
- Interventions
- Drug: MT-3995 HighDrug: MT-3995 LowDrug: MT-3995 Middle
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 241
- Registration Number
- NCT02676401
- Locations
- 🇯🇵
Touei Hospital, Hokkaido, Japan
A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 28
- Registration Number
- NCT02675309
- Locations
- 🇬🇧
Investigational center, City name, United Kingdom
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 139
- Registration Number
- NCT02622113
- Locations
- 🇯🇵
Reserch site, Tohoku, Japan
A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT02536209
- Locations
- 🇬🇧
Investigational center, City name, United Kingdom
Drug Interaction Study of Warfarin and MT-3995
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT02531568
- Locations
- 🇩🇪
Clinical research organization, Neu-Ulm, Wegenerstraße, Germany
Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
Phase 2
Completed
- Conditions
- Diabetic Nephropathy
- Interventions
- Drug: MT-3995 LowDrug: MT-3995 HighDrug: PlaceboDrug: MT-3995 Middle
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 293
- Registration Number
- NCT02517320
- Locations
- 🇯🇵
Investigational site, Hokkaido, Japan
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 135
- Registration Number
- NCT02429102
- Locations
- 🇬🇧
Investigational center, City name, United Kingdom